Medrx Co

Medrx Co Depreciation & Amortization

The Depreciation & Amortization of Medrx Co (4586.T) as of Nov 19, 2026 is 1.24 M JPY. In the previous year, Depreciation & Amortization was 2.34 M JPY — a change of -46.72% (lower).

Depreciation & Amortization

1.24 MJPY

YoY

-46.72%

Last updated:

Depreciation & Amortization of Medrx Co is 2024 1.24 M JPY. Depreciation & Amortization of Medrx Co was 2023 2.34 M JPY. It decreases by -46.72% lower compared to the previous year.

The Medrx Co Depreciation & Amortization history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Depreciation & Amortization
Date
Depreciation & Amortization
Jan 1, 2017
3.08 M JPY
Jan 1, 2018
3.02 M JPY
Jan 1, 2019
2.94 M JPY
Jan 1, 2020
3.48 M JPY
Jan 1, 2021
3.41 M JPY
Jan 1, 2022
2.39 M JPY
Jan 1, 2023
2.34 M JPY
Jan 1, 2024
1.24 M JPY
The Medrx Co Depreciation & Amortization history
YEARDepreciation & AmortizationYoY
1.24 MJPY-46.72%
2.34 MJPY-2.30%
2.39 MJPY-29.95%
3.41 MJPY-1.81%
3.48 MJPY+18.16%
2.94 MJPY-2.62%
3.02 MJPY-1.82%
3.08 MJPY-10.14%
3.42 MJPY-5.73%
3.63 MJPY-6.90%
3.90 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Medrx Co Stock analysis

What does Medrx Co do? Medrx Co. Ltd. develops pharmaceutical drugs using transdermal absorption technology, focusing on percutaneous absorption through ionic liquid transdermal system (ILTS) and nano-sized colloid transdermal system (NCTS). The company aims to maximize drug efficacy, reduce side effects, and provide alternatives for patients who cannot take oral medications. Its products target new markets by offering medicines with enhanced delivery systems and added value. The firm's technology includes ionic liquid transdermal system (ILTS) leveraging ionic liquid characteristics and nano-sized colloid transdermal system (NCTS) utilizing nano colloidization technology. These systems enable precise drug delivery, addressing challenges in oral administration and improving patient compliance. The company's products are designed to serve patients requiring non-oral medication options. Medrx Co. Ltd. produces medicines based on percutaneous absorption formulation technology, targeting healthcare providers and patients who need alternative drug administration methods. The company's focus on transdermal systems allows it to address specific medical needs, such as preventing forgotten doses and reducing side effects associated with traditional oral drugs. Medrx Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Medrx Co stock

Depreciation & Amortization of Medrx Co is 1.24 M JPY in 2024.

Depreciation & Amortization of Medrx Co changed from 2.34 M JPY to 1.24 M JPY, representing a -46.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Depreciation & Amortization Medrx Co since 2006 – with annual values, charts, and detailed analysis.

Depreciation & Amortization represents the allocation of the cost of tangible and intangible assets over their useful lives.

Depreciation & Amortization's JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Depreciation & Amortization's Medrx Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Medrx Co

All Key Metrics — Medrx Co